Nuvalent Enters Material Definitive Agreement

Ticker: NUVL · Form: 8-K · Filed: Nov 20, 2025 · CIK: 1861560

Sentiment: neutral

Topics: material-agreement, filing

TL;DR

Nuvalent just signed a big deal, filing an 8-K to let everyone know.

AI Summary

Nuvalent, Inc. announced on November 18, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Cambridge, Massachusetts, filed this 8-K report to disclose this event. Further details regarding the agreement are expected to be provided.

Why It Matters

This filing indicates a significant new contract or partnership for Nuvalent, Inc., which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry significant risks depending on the nature of the agreement, which is not fully detailed in this initial filing.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Nuvalent, Inc.?

The filing states that Nuvalent, Inc. entered into a material definitive agreement on November 18, 2025, but the specific details of this agreement are not provided in this initial 8-K report.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on November 18, 2025.

What is Nuvalent, Inc.'s state of incorporation?

Nuvalent, Inc. is incorporated in Delaware.

Where are Nuvalent, Inc.'s principal executive offices located?

Nuvalent, Inc.'s principal executive offices are located at One Broadway, 14th Floor, Cambridge, Massachusetts 02142.

What is the SEC file number for Nuvalent, Inc.?

The SEC file number for Nuvalent, Inc. is 001-40671.

Filing Stats: 1,346 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2025-11-20 06:01:19

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated November 18, 2025, by and among the Company, Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co. 5.1 Opinion of Sidley Austin LLP. 23.1 Consent of Sidley Austin LLP (included in Exhibit 5.1). 99.1 Press Release issued by the Company on November 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvalent, Inc. Date: November 20, 2025 By: /s/ Deborah Miller Deborah Miller, Ph.D. Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing